Paperpal Prime Logo

Therapeutic Innovation and Regulatory Science : Impact Factor & More

eISSN: 2168-4804pISSN: 2168-4790

Aims and Scope of Therapeutic Innovation and Regulatory Science

Therapeutic Innovation & Regulatory Science is a bimonthly peer-reviewed medical journal that covers research and developments concerning pharmaceuticals and the development and use of medical products. It is published by Sage Publications on behalf of the Drug Information Association. The journal was established in 1967 as the Drug Information Bulletin and renamed to Drug Information Journal in 1971, before obtaining its current title in 2013. The editor-in-chief is Stephen P. Spielberg. Less

Key Metrics

CiteScore
2.2
H-Index
48
Impact Factor
< 5
SJR
Q2Pharmacology (medical)
SNIP
0.6
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Therapeutic Innovation and Regulatory Science

Therapeutic Innovation and Regulatory Science Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher SPRINGER HEIDELBERG
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year1966
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Therapeutic Innovation and Regulatory Science ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Therapeutic Innovation and Regulatory Science

Leveraging Regulatory Reliance to Streamline Management of CMC Post-Approval Changes: Industry insights from Multi-Country Reliance Pilots.
  • 24 Oct 2026
  • Therapeutic innovation & regulatory science
The Role of Digital Twins in Clinical Trials: A New Perspective on Methodological and Statistical Challenges.
  • 23 Oct 2026
  • Therapeutic innovation & regulatory science
Japanese Patient Enrollment in Multi-regional Clinical Trials for New Drug Applications in Japan: Current Status and Related Factors.
  • 23 Oct 2026
  • Therapeutic innovation & regulatory science
Investigator-Initiated Trials as a Clinical Development Approach for Orphan Drugs Compared with Industry-Sponsored Trials in Japan.
  • 23 Oct 2026
  • Therapeutic innovation & regulatory science
Accelerated Registration of a New Anti-infective Combination in ASEAN Markets: Experience, Insights and Learnings on the ASEAN Joint Assessment (ASEAN JA).
  • 22 Oct 2026
  • Therapeutic innovation & regulatory science
A Pragmatic Implementation Framework for Phase 2 Trials with Invasive Endpoints: Estimands, Missing Outcomes, and Decision-Ready Evidence.
  • 21 Oct 2026
  • Therapeutic innovation & regulatory science
Leveraging Regulatory Reliance to Streamline Management of CMC Post-Approval Changes: Industry insights from Multi-Country Reliance Pilots.
  • 24 Oct 2026
  • Therapeutic innovation & regulatory science
The Role of Digital Twins in Clinical Trials: A New Perspective on Methodological and Statistical Challenges.
  • 23 Oct 2026
  • Therapeutic innovation & regulatory science
Japanese Patient Enrollment in Multi-regional Clinical Trials for New Drug Applications in Japan: Current Status and Related Factors.
  • 23 Oct 2026
  • Therapeutic innovation & regulatory science
Investigator-Initiated Trials as a Clinical Development Approach for Orphan Drugs Compared with Industry-Sponsored Trials in Japan.
  • 23 Oct 2026
  • Therapeutic innovation & regulatory science
Accelerated Registration of a New Anti-infective Combination in ASEAN Markets: Experience, Insights and Learnings on the ASEAN Joint Assessment (ASEAN JA).
  • 22 Oct 2026
  • Therapeutic innovation & regulatory science
A Pragmatic Implementation Framework for Phase 2 Trials with Invasive Endpoints: Estimands, Missing Outcomes, and Decision-Ready Evidence.
  • 21 Oct 2026
  • Therapeutic innovation & regulatory science

FAQs on Therapeutic Innovation and Regulatory Science